Thursday, October 05, 2017 2:03:35 PM
Dr. Ben-Zion Weiner, PhD
SCIENTIFIC ADVISORY BOARD CHAIRMAN
Dr. Ben-Zion Weiner was Head of Global
Research and Development at Teva
Pharmaceutical Industries Ltd. for over three
decades, including as a member of the Teva
Executive Committee. He directly oversaw all
pharmaceutical development and regulatory
approval of Teva’s innovative product pipeline.
Dr. Weiner was also responsible for the
development of hundreds of generic products
for the US, European, and other markets. He
received a BSc degree in general chemistry
and biochemistry and an MSc degree in
organic chemistry, graduating with distinction
for both degrees from the Hebrew University,
Jerusalem. He received his PhD degree in
chemistry at the Hebrew University,
Jerusalem, and conducted his post-doctoral
research at Schering-Plough Corporation in
the United States. http://www.otipharma.com/wp-content/uploads/2017/03/OT-short-presentation-03-16-2017-V-2.0.pdf
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM